On September 12, 2023 CyGenica Limited, a dynamic biotech startup reported a significant achievement in the battle against Glioblastoma Multiforme (GBM), a highly aggressive form of brain cancer (Press release, CyGenica, SEP 12, 2023, View Source [SID1234635121]). Dr. Nusrat J M Sanghamitra, Co-founder and CEO of CyGenica, revealed that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation for their revolutionary drug conjugate for the treatment of GBM. This momentous approval represents a significant advancement for CyGenica’s innovative intracellular delivery platform, GEENIE, and offers new avenues of hope for patients fighting cancer and rare diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
GBM continues to pose a formidable challenge in the field of oncology, calling for novel and effective treatment approaches. CyGenica’s Orphan Drug Designation approval for their novel drug conjugate demonstrates a resolute commitment to address the unmet medical needs of GBM patients.
This momentous achievement marks a pivotal milestone in CyGenica’s journey as the first application of their targeted intracellular delivery platform, GEENIE, for any disease indication. Beyond GBM, the company envisions a world where GEENIE empowers the development of innovative therapies for various cancers and rare diseases, including nucleotide-based therapeutics like antisense oligonucleotides, SiRNAs, and genome editing therapeutics.
Dr. Nusrat J M Sanghamitra stated, "We are incredibly thrilled to receive the USFDA’s approval for our Orphan Drug Designation for our novel drug conjugate in GBM treatment. This validation paves the way for CyGenica to push the boundaries of innovation and expand our intracellular delivery platform, GEENIE to bring hope to countless patients."
As CyGenica continues to advance their novel drug conjugate and GEENIE platform, the company is eager to collaborate with biotech investors and pharmaceutical companies.
"This is a remarkable opportunity for potential partners to join us in the global fight against GBM, other types of cancers, and rare diseases," Dr. Sanghamitra emphasized. "Together, we can unlock the full potential of GEENIE and create a lasting impact on the lives of patients worldwide."